whatshot

CRSP   $48.02  -1.01% Market Closed After Close 48.4936 0.99%

CRISPR Therapeutics AG
show_chart Advanced Chart of CRSP
Last Events:

2023-08-09 Trend pattern changed from расходящийся клин с наклоном вниз to нисходящий клин.

2023-08-04 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: signal line crossed the middle level.

2023-08-04 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it crossed the signal line from the top and falls. These factors mean that the market confirms the tendency to fall. Last signal: main and signal line crossing.

2023-08-04 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-04 Trend Power changed from slow to almost flat.

2023-08-03 Trend pattern changed from нисходящий треугольник to расходящийся клин с наклоном вниз.

2023-08-03 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: signal line crossed the middle level.

2023-08-03 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

Current temperature: 13.46
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 24
Target Price Mean 80.92
Mean unverified/preliminary 80.92 / 80.92
Target Price Low / High 30.00 / 199.00
Median / STD DEV 76.00 / 34.70
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Sell Sell
rsi ActivelyBuy Sell Sell
macd Sell None None
stoch Sell None None
ma20 ActivelyBuy None None
ma50 Sell None None
ma100 Buy Sell None
Candlestick PatternOct. 21, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN CH0334081137
ceo Dr. Samarth Kulkarni Ph.D.
Website https://www.crisprtx.com
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.